{"generic":"Etanercept","drugs":["Enbrel","Etanercept"],"mono":{"0":{"id":"924808-s-0","title":"Generic Names","mono":"Etanercept"},"1":{"id":"924808-s-1","title":"Dosing and Indications","sub":{"0":{"id":"924808-s-1-4","title":"Adult Dosing","mono":"<ul><li>prior to initiating therapy and periodically during therapy, evaluate for active TB and test for latent TB<\/li><li><b>Ankylosing spondylitis:<\/b> 50 mg SUBQ weekly<\/li><li><b>Plaque psoriasis, chronic (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy:<\/b> initial, 50 mg SUBQ twice weekly for 3 months; starting doses of 25 or 50 mg once weekly have also shown efficacy<\/li><li><b>Plaque psoriasis, chronic (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy:<\/b> maintenance, 50 mg SUBQ weekly<\/li><li><b>Psoriatic arthritis:<\/b> 50 mg SUBQ weekly<\/li><li><b>Rheumatoid arthritis (Moderate to Severe):<\/b> 50 mg SUBQ weekly<\/li><\/ul>"},"1":{"id":"924808-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>prior to initiating therapy and periodically during therapy, evaluate for active TB and test for latent TB<\/li><li><b>Juvenile idiopathic arthritis (Moderate to Severe):<\/b> (2 years or older, less than 63 kg) 0.8 mg\/kg SUBQ weekly<\/li><li><b>Juvenile idiopathic arthritis (Moderate to Severe):<\/b> (2 years or older, 63 kg or greater) 50 mg SUBQ weekly<\/li><\/ul>"},"3":{"id":"924808-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Ankylosing spondylitis<\/li><li>Juvenile idiopathic arthritis (Moderate to Severe)<\/li><li>Plaque psoriasis, chronic (Moderate to Severe), In patients who are candidates for systemic therapy or phototherapy<\/li><li>Psoriatic arthritis<\/li><li>Rheumatoid arthritis (Moderate to Severe)<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Graft versus host disease<\/li><li>Hidradenitis suppurativa, Severe, refractory<\/li><\/ul>"}}},"2":{"id":"924808-s-2","title":"Black Box Warning","mono":"<b>Subcutaneous (Solution; Powder for Solution)<\/b><br\/>Patients treated with etanercept are at increased risk for infections, some progressing to serious infections leading to hospitalization or death. These infections have included bacterial sepsis, tuberculosis, invasive fungal and other opportunistic infections, including Legionella and Listeria. Evaluate for latent tuberculosis and treat if necessary prior to initiation of therapy. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept.<br\/>"},"3":{"id":"924808-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924808-s-3-9","title":"Contraindications","mono":"sepsis <br\/>"},{"id":"924808-s-3-10","title":"Precautions","mono":"<ul><li>children, adolescents, and young adults; lymphoma and other cancers, including fatalities, have been reported postmarketing<\/li><li>hepatosplenic T-cell lymphoma has been reported primarily in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, including etanercept, for Crohn's disease or ulcerative colitis; most cases were fatal and occurred with concomitant use of azathioprine or mercaptopurine; carefully assess risk\/benefit of using TNF blockers, azathioprine, and\/or mercaptopurine in adolescents and young adults, especially for the treatment of Crohn's disease or ulcerative colitis<\/li><li>infection, chronic or recurring, predisposing factors (eg, advanced or poorly controlled diabetes), or history of opportunistic infection; evaluate risk\/benefit; monitoring recommended; discontinue if serious infection develops<\/li><li>serious infections (eg, bacterial (Legionella and Listeria), tuberculosis, invasive fungal infections, viral, parasitic, and other opportunistic infections), including fatalities, have been reported, especially with concomitant immunosuppressant use; do not initiate therapy in patients with active infections (including chronic or localized infections); evaluate risk\/benefit for travel or residence in areas of endemic TB or mycoses; monitoring recommended; discontinue therapy if a serious infection develops<\/li><li>TB, reactivation or new-onset, may occur; increased risk in patients with potential exposure due to travel or residence in endemic areas or close personal contact with active TB or with history of latent or active disease, regardless of previous Bacille Calmette-Guerin vaccination<\/li><li>alcoholic hepatitis, moderate to severe; increased mortality after 6 months of treatment<\/li><li>allergic reactions have been reported; may require discontinuation of therapy and medical management<\/li><li>autoantibody formation has occurred and may develop into lupus-like syndrome or autoimmune hepatitis; discontinue therapy if symptoms occur<\/li><li>concomitant use of abatacept, anakinra, cyclophosphamide, or live vaccines is not recommended<\/li><li>congestive heart failure, new-onset or worsening of preexisting disease has been reported even in absence of risk factors; monitoring recommended; discontinuation of therapy may be necessary<\/li><li>demyelinating disorders (eg, transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barre syndromes, seizure disorders, peripheral demyelinating neuropathies); new onset or worsening of preexisting central or peripheral demyelinating disorders has been reported, especially in patients with preexisting or recent-onset disorders<\/li><li>diabetes; hypoglycemia has been reported<\/li><li>elderly patients greater than 65 years of age; increased risk of infection<\/li><li>hematological abnormalities (eg, pancytopenia, aplastic anemia), including fatalities, have occurred; increased risk in patients with a history of hematological abnormalities; may require discontinuation of therapy<\/li><li>hepatitis B, chronic carriers; reactivation has occurred including several months after therapy termination; monitoring recommended; discontinuation and supportive treatment may be necessary<\/li><li>latex sensitivity; needle cover of prefilled syringe and on SureClick autoinjector contains latex<\/li><li>malignancies (lymphomas, acute and chronic leukemia) have been reported; patients with rheumatoid arthritis may be at higher risk for developing lymphomas and leukemias than the general population<\/li><li>melanoma, non-melanoma, and Merkel cell skin cancers have been reported; monitoring recommended in all patients at risk<\/li><li>pediatric patients should be brought up-to-date on all immunization requirements, when possible, prior to beginning treatment with etanercept<\/li><li>varicella virus exposure, significant; temporarily discontinue treatment; consider prophylactic treatment<\/li><li>Wegener's granulomatosis with concomitant immunosuppressive agents; use is not recommended<\/li><li>report suspected adverse reactions to the US Food and Drug Administration 1-800-FDA-1088, or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924808-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"924808-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924808-s-4","title":"Drug Interactions","sub":{"1":{"id":"924808-s-4-14","title":"Major","mono":"<ul><li>Abatacept (established)<\/li><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Anakinra (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Cyclophosphamide (probable)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><\/ul>"}}},"5":{"id":"924808-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (plaque psoriasis, 15%; rheumatoid arthritis, 37% to 43%)<\/li><li><b>Respiratory:<\/b>Rhinitis (12% to 14%), Upper respiratory infection (17% to 65%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure (0.1% or less)<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Malignant melanoma, Necrotizing fasciitis, Primary cutaneous vasculitis, Skin cancer, Squamous cell carcinoma of skin, Stevens-Johnson syndrome, Toxic epidermal necrolysis due to drug<\/li><li><b>Hematologic:<\/b>Anemia, Aplastic anemia (less than 0.01%), Leukopenia, Neutropenia, Pancytopenia (less than 0.1%), Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Autoimmune hepatitis (less than 1%), Cancer, Hypersensitivity reaction (less than 2%), Malignant lymphoma, T-cell lymphoma, hepatosplenic<\/li><li><b>Neurologic:<\/b>Demyelinating disease of central nervous system (less than 0.1%), Guillain-Barr  syndrome, Multiple sclerosis, Seizure, Transverse myelitis, acute<\/li><li><b>Ophthalmic:<\/b>Optic neuritis<\/li><li><b>Respiratory:<\/b>Legionella pneumonia, Tuberculosis (0.006% to 0.02%)<\/li><li><b>Other:<\/b>Cancer (0.2%), Infectious disease, Legionella pneumonia, Leukemia, Listeriosis, Malignant lymphoma, T-cell lymphoma, hepatosplenic<\/li><\/ul>"},"6":{"id":"924808-s-6","title":"Drug Name Info","sub":{"0":{"id":"924808-s-6-17","title":"US Trade Names","mono":"Enbrel<br\/>"},"2":{"id":"924808-s-6-19","title":"Class","mono":"<ul><li>Immune Suppressant<\/li><li>Tumor Necrosis Factor Inhibitor<\/li><\/ul>"},"3":{"id":"924808-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924808-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"924808-s-7","title":"Mechanism Of Action","mono":"Etanercept is a dimeric soluble form of the p75 tumor necrosis factor (TNF) receptor that specifically binds TNF alpha and TNF beta. The binding of etanercept to TNF, a naturally occurring cytokine involved in normal inflammatory and immune responses, renders it biologically inactive. Etanercept also modulates biologic responses that are induced or regulated by TNF, including expression of adhesion molecules responsible for leukocyte migration, serum levels of cytokines, and serum levels of matrix metalloproteinase.<br\/>"},"8":{"id":"924808-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"924808-s-8-23","title":"Absorption","mono":"Bioavailability, subcutaneous: 58% <br\/>"},"1":{"id":"924808-s-8-24","title":"Distribution","mono":"Vd: 12 L (range 6 L to 18 L) <br\/>"},"2":{"id":"924808-s-8-25","title":"Metabolism","mono":"Reticuloendothelial system (speculated) <br\/>"},"4":{"id":"924808-s-8-27","title":"Elimination Half Life","mono":"102 +\/- 30 h<br\/>"}}},"9":{"id":"924808-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>needle cover of the prefilled syringe and autoinjector contains dry natural rubber and should not be handled by persons sensitive to latex<\/li><li>(prefilled syringe and autoinjector) leave syringe for 15 to 30 minutes at room temperature before injecting; do not remove needle cover while allowing the syringe to reach room temperature<\/li><li>(autoinjector) do not use single-use prefilled syringe if the amount of liquid does not fall between the 2 purple fill level indicator lines on the syringe<\/li><li>(multiple-use vial) use vial adapter during reconstitution if only 1 dose will be withdrawn; use 25-gauge needle if multiple doses will be withdrawn<\/li><li>(multiple-use vial) inject 1 mL of supplied sterile bacteriostatic water for injection, USP, slowly into vial and swirl gently; some foaming is normal<\/li><li>do not shake vial or syringe<\/li><li>(multiple-use vial) do not filter during preparation or administration<\/li><li>(multiple-use vial) do not add any other medications to the reconstituted solution; do not use any other diluents except sterile bacteriostatic water for injection, USP<\/li><li>(multiple-use vial) following reconstitution, store in refrigerator and use within 14 days of reconstitution<\/li><li>visually inspect solution prior to administration; do not use if solution is cloudy, or if particulate matter is present<\/li><li>(multiple-use vial) inject using 27-gauge needle<\/li><li>(autoinjector) do not touch the purple button until the safety guard is fully retracted against the skin<\/li><\/ul>"},"10":{"id":"924808-s-10","title":"Monitoring","mono":"<ul><li>rheumatoid arthritis: erythrocyte sedimentation rate, rheumatoid factor, and C-reactive protein may be measured for indication of efficacy<\/li><li>psoriatic arthritis: C-reactive protein may be measured for indication of efficacy<\/li><li>rheumatoid arthritis: improvement in duration and severity of morning stiffness, number of tender and\/or swollen joints, range of motion, pain, and quality of life (eg, physical function and disability)<\/li><li>psoriatic arthritis: improvement in duration and severity of morning stiffness, number of tender and\/or swollen joints, pain, physical function and disability measures, and skin lesions<\/li><li>ankylosing spondylitis: improvement in back pain and spinal mobility<\/li><li>plaque psoriasis: improvement in the fraction of body surface area affected, and degree of induration, erythema, and scaling.<\/li><li>rheumatoid and psoriatic arthritis: improvement in radiographic progression of disease<\/li><li>fungal cultures, histopathological or cytological assessments, antigen detection, and serum antibody titers in patients suspected of developing a fungal infection during or after tumor necrosis factor blocker therapy<\/li><li>hepatitis B virus (HBV); in at-risk patients for HBV infection and carrier status prior to therapy; in patients who are identified as HBV carriers, active HBV infection during therapy and for several months after discontinuation<\/li><li>liver function tests; during therapy<\/li><li>active or latent TB infection and TB risk factors; prior to, during, and after therapy, even in patients who had a negative tuberculin test prior to treatment initiation; particularly with risk factors for TB infection (eg, history of TB infection, traveled or resided in TB endemic areas, close contact with persons with active TB)<\/li><li>congestive heart failure; new or worsening symptoms of preexisting disease<\/li><li>periodic skin evaluations; in patients at increased risk for skin cancer<\/li><li>signs or symptoms of invasive fungal infection (eg, histoplasmosis, coccidioidomycosis, blastomycosis, or other opportunistic infections (eg, legionella, listeria))<\/li><\/ul>"},"11":{"id":"924808-s-11","title":"How Supplied","mono":"<b>Enbrel<\/b><br\/><ul><li>Subcutaneous Powder for Solution: 25 MG<\/li><li>Subcutaneous Solution: 50 MG\/ML<\/li><\/ul>"},"13":{"id":"924808-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel patient on the increased risk of infection and to report signs\/symptoms of an infection or a recurring infection (hepatitis B, tuberculosis) during therapy and for several months after discontinuation.<\/li><li>Advise patient of increased risk of lymphoma and other malignancies and to report persistent fevers, night sweats, or significant weight loss.<\/li><li>Warn patient to avoid live vaccines during therapy due to drug-induced immunosuppression, and to report an exposure to varicella virus immediately.<\/li><li>Instruct patient to report a latex sensitivity prior to use, as needle cap on prefilled syringe and autoinjector contains dry natural rubber (latex derivative).<\/li><li>Drug may cause abdominal pain, vomiting, cough, rhinitis, anemia, leukopenia, neutropenia, or thrombocytopenia.<\/li><li>Advise patient to report signs\/symptoms of a lupus-like syndrome, myelosuppression, or pancytopenia.<\/li><li>Counsel patient about proper injection sites and rotation.<\/li><\/ul>"}}}